Literature DB >> 17587360

Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects.

R E Kast1, K F Foley.   

Abstract

Mirtazapine and olanzapine are easy-to-use psychiatric drugs with potent antinausea effects. Ondansetron and later members of the 'setron class are currently standard treatments for cancer chemotherapy-related nausea and emesis. They are potent 5-HT3 blockers, but it is often not appreciated that mirtazapine and olanzapine bind with similar affinity to 5-HT3 receptors, have a longer half-life, are considerably cheaper than the 'setron class, and often offer better and smoother 24-h nausea control than 'setron class drugs. Mirtazapine and olanzapine often have salutary antianxiety effects and improve sleep quality. They occasionally relieve chemotherapy-related and advanced cancer-related nausea and appetite decrease better than the 'setron group that are specifically marketed for nausea control. Mirtazapine and olanzapine frequently give potent nausea reduction and appetite increase in advanced cancer-related cachexia. Several cytokine changes potentially induced by mirtazapine and olanzapine use are discussed that may have salutary effects in several cancers. We suggest mirtazapine and olanzapine be included as first-line options in treating both chemotherapy- and advanced cancer-related nausea. Multiple clinical and economic advantages of mirtazapine and olanzapine over currently used 'setron class medicines are reviewed. Double-blind studies against the 'setron class drugs are warranted.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17587360     DOI: 10.1111/j.1365-2354.2006.00760.x

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  30 in total

1.  Determination of mirtazapine in spiked human plasma and tablets by first derivative spectrofluorimetric method.

Authors:  Rasha M Youssef
Journal:  Saudi Pharm J       Date:  2010-01-06       Impact factor: 4.330

Review 2.  Psychopharmacology in psycho-oncology.

Authors:  Rosangela Caruso; Luigi Grassi; Maria Giulia Nanni; Michelle Riba
Journal:  Curr Psychiatry Rep       Date:  2013-09       Impact factor: 5.285

3.  Olanzapine is effective for refractory chemotherapy-induced nausea and vomiting irrespective of chemotherapy emetogenicity.

Authors:  Sierra Vig; Laurel Seibert; Myke R Green
Journal:  J Cancer Res Clin Oncol       Date:  2013-10-31       Impact factor: 4.553

4.  Mirtazapine inhibits tumor growth via immune response and serotonergic system.

Authors:  Chun-Kai Fang; Hong-Wen Chen; I-Tsang Chiang; Chia-Chieh Chen; Jyh-Fei Liao; Ton-Ping Su; Chieh-Yin Tung; Yosuke Uchitomi; Jeng-Jong Hwang
Journal:  PLoS One       Date:  2012-07-13       Impact factor: 3.240

5.  [Mirtazapine and hyperemesis gravidarum].

Authors:  M Lieb; U Palm; D Jacoby; T C Baghai; E Severus
Journal:  Nervenarzt       Date:  2012-03       Impact factor: 1.214

Review 6.  Treatment of chemotherapy-induced nausea and vomiting.

Authors:  Hanane Inrhaoun; Tamás Kullmann; Ibrahim Elghissassi; Hind Mrabti; Hassan Errihani
Journal:  J Gastrointest Cancer       Date:  2012-12

Review 7.  The Black Book of Psychotropic Dosing and Monitoring.

Authors:  Alan F Schatzberg; DeBattista Charles
Journal:  Psychopharmacol Bull       Date:  2018-01-15

8.  [Dyspnea, itching and depression in palliative medicine].

Authors:  M Mücke; R Conrad; M Bleckwenn; H Cuhls; L Radbruch; R Rolke
Journal:  Schmerz       Date:  2016-04       Impact factor: 1.107

9.  Mirtazapine improves sleep and lowers anxiety and depression in cancer patients: superiority over imipramine.

Authors:  Eylem Sahin Cankurtaran; Elvan Ozalp; Haldun Soygur; Derya Iren Akbiyik; Levent Turhan; Necati Alkis
Journal:  Support Care Cancer       Date:  2008-02-26       Impact factor: 3.603

10.  Drug exposure and clinical effect of transdermal mirtazapine in healthy young cats: a pilot study.

Authors:  Kellyi K Benson; Lara B Zajic; Paula K Morgan; Sarah R Brown; Ryan J Hansen; Paul J Lunghofer; Luke A Wittenburg; Daniel L Gustafson; Jessica M Quimby
Journal:  J Feline Med Surg       Date:  2016-09-01       Impact factor: 2.015

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.